Identification

Name
Tranylcypromine
Accession Number
DB00752  (APRD00645)
Type
Small Molecule
Groups
Approved, Investigational
Description

A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311).

Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).

Structure
Thumb
Synonyms
  • (±)-trans-2-phenylcyclopropylamine
  • (1R*,2S*)-2-phenylcyclopropan-1-amine
  • DL-tranylcypromine
  • Racemic Tranylcypromine
  • Tranilcipromina
  • trans-2-phenylcyclopropylamine
  • trans-DL-2-Phenylcyclopropylamine
  • Transamine
  • Tranylcypromin
  • Tranylcypromine
  • Tranylcyprominum
External IDs
SKF 385 / SKF Trans-385
Product Ingredients
IngredientUNIICASInChI Key
Tranylcypromine sulfate7ZAT6ES87013492-01-8BKPRVQDIOGQWTG-KAVFMPKWSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ParnateTablet, film coated10 mg/1OralGlaxosmithkline Inc1989-06-232014-04-01Us0007 447120180907 15195 cu3siv
ParnateTablet10 mgOralGlaxosmithkline Inc1992-12-31Not applicableCanada
ParnateTablet, film coated10 mg/1OralGlaxosmithkline Inc2013-01-14Not applicableUs
ParnateTablet, film coated10 mg/1OralConcordia Pharmaceuticals, Inc2013-01-14Not applicableUs
ParnateTablet, film coated10 mg/1OralCovis Pharmaceuticals, Inc.2013-01-142017-09-30Us
ParnateTablet, film coated10 mg/1OralPhysicians Total Care, Inc.1994-08-152011-06-30Us
Tranylcypromine SulfateTablet10 mg/1OralRising Pharmaceuticals2012-01-09Not applicableUs
Tranylcypromine SulfateTablet10 mg/1OralRemedy Repack2014-04-012016-12-16Us64980 0183 01 nlmimage10 4b47a5dd
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tranylcypromine SulfateTablet10 mg/1OralGolden State Medical Supply2013-10-18Not applicableUs
Tranylcypromine SulfateTablet, film coated10 mg/1OralActavis Pharma Company2016-02-05Not applicableUs
Tranylcypromine SulfateTablet10 mg/1OralPar Pharmaceutical2006-06-30Not applicableUs
International/Other Brands
Jatrosom (Aristo Pharma)
Categories
UNII
3E3V44J4Z9
CAS number
155-09-9
Weight
Average: 133.194
Monoisotopic: 133.089149358
Chemical Formula
C9H11N
InChI Key
AELCINSCMGFISI-UHFFFAOYSA-N
InChI
InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2
IUPAC Name
2-phenylcyclopropan-1-amine
SMILES
NC1CC1C1=CC=CC=C1

Pharmacology

Indication

For the treatment of major depressive episode without melancholia.

Associated Conditions
Pharmacodynamics

Tranylcypromine belongs to a class of antidepressants called monoamine oxidase inhibitors (MAOIs). Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor with a rapid onset of activity. MAO is an enzyme that catalyzes the oxidative deamination of a number of amines, including serotonin, norepinephrine, epinephrine, and dopamine. Two isoforms of MAO, A and B, are found in the body. MAO-A is mainly found within cells located in the periphery and catalyzes the breakdown of serotonin, norepinephrine, epinephrine, dopamine and tyramine. MAO-B acts on phenylethylamine, norepinephrine, epinephrine, dopamine and tyramine, is localized extracellularly and is found predominantly in the brain. While the mechanism of MAOIs is still unclear, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. It has been postulated that depression is caused by low levels of serotonin and/or norepinephrine and that increasing serotonergic and norepinephrinergic neurotransmission results in relief of depressive symptoms. MAO A inhibition is thought to be more relevant to antidepressant activity than MAO B inhibition. Selective MAO B inhibitors, such as selegiline, have no antidepressant effects.

Mechanism of action

Tranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.

TargetActionsOrganism
AAmine oxidase [flavin-containing] A
inhibitor
Human
AAmine oxidase [flavin-containing] B
inhibitor
Human
Absorption

Interindividual variability in absorption. May be biphasic in some individuals. Peak plasma concentrations occur in one hour following oral administration with a secondary peak occurring within 2-3 hours. Biphasic absorption may represent different rates of absorption of the stereoisomers of the drug, though additional studies are required to confirm this.

Volume of distribution

1.1-5.7 L/kg

Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life

1.5-3.2 hours in patients with normal renal and hepatic function

Clearance
Not Available
Toxicity

In overdosage, some patients exhibit insomnia, restlessness and anxiety, progressing in severe cases to agitation, mental confusion and incoherence. Hypotension, dizziness, weakness and drowsiness may occur, progressing in severe cases to extreme dizziness and shock. A few patients have displayed hypertension with severe headache and other symptoms. Rare instances have been reported in which hypertension was accompanied by twitching or myoclonic fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing to generalized rigidity and coma.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with (R)-warfarin.Experimental
(S)-WarfarinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with (S)-Warfarin.Experimental, Investigational
2,4-thiazolidinedioneTranylcypromine may increase the hypoglycemic activities of 2,4-thiazolidinedione.Investigational
2,5-Dimethoxy-4-ethylamphetamineTranylcypromine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineTranylcypromine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineTranylcypromine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,5-DinitrocatecholThe risk or severity of adverse effects can be increased when 3,5-Dinitrocatechol is combined with Tranylcypromine.Experimental
4-Bromo-2,5-dimethoxyamphetamineTranylcypromine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-hydroxycoumarinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with 4-hydroxycoumarin.Experimental
4-MethoxyamphetamineTranylcypromine may increase the hypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Tranylcypromine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Abciximab.Approved
AbediterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Abediterol.Investigational
AcarboseTranylcypromine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololTranylcypromine may increase the hypotensive activities of Acebutolol.Approved, Investigational
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideTranylcypromine may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetophenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acetylglycinamide chloral hydrate.Experimental
Acetylsalicylic acidThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Acetylsalicylic acid.Approved, Vet Approved
AdinazolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideTranylcypromine may increase the hypoglycemic activities of AICA ribonucleotide.Experimental, Investigational
AlaproclateTranylcypromine may increase the serotonergic activities of Alaproclate.Experimental
AlbiglutideTranylcypromine may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Tranylcypromine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alcuronium.Experimental
AldesleukinTranylcypromine may increase the orthostatic hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of hypertension, serotonin syndrome, and CNS depression can be increased when Tranylcypromine is combined with Alfentanil.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alimemazine.Approved, Vet Approved
AliskirenTranylcypromine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllobarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Allopregnanolone.Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Tranylcypromine.Approved, Investigational
AlogliptinTranylcypromine may increase the hypoglycemic activities of Alogliptin.Approved
AlosetronThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tranylcypromine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Tranylcypromine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tranylcypromine.Approved, Illicit, Investigational
AlprenololTranylcypromine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AlteplaseThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Alteplase.Approved
AltretamineAltretamine may increase the orthostatic hypotensive activities of Tranylcypromine.Approved
AlverineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alverine.Approved, Investigational
AmantadineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Amantadine.Approved
AmbrisentanTranylcypromine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmediplaseThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Amediplase.Investigational
AMG-222Tranylcypromine may increase the hypoglycemic activities of AMG-222.Investigational
AmifostineTranylcypromine may increase the orthostatic hypotensive activities of Amifostine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideTranylcypromine may increase the orthostatic hypotensive activities of Amiloride.Approved
AmineptineTranylcypromine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmiodaroneTranylcypromine may increase the orthostatic hypotensive activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amisulpride.Approved, Investigational
AmitriptylineTranylcypromine may increase the serotonergic activities of Amitriptyline.Approved
AmitriptylinoxideTranylcypromine may increase the serotonergic activities of Amitriptylinoxide.Approved, Investigational
AmlodipineTranylcypromine may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Tranylcypromine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amperozide.Experimental
AmphetamineTranylcypromine may increase the hypertensive activities of Amphetamine.Approved, Illicit, Investigational
Amphotericin BTranylcypromine may increase the orthostatic hypotensive activities of Amphotericin B.Approved, Investigational
Amyl NitriteTranylcypromine may increase the orthostatic hypotensive activities of Amyl Nitrite.Approved
AnagliptinTranylcypromine may increase the hypoglycemic activities of Anagliptin.Investigational
AnagrelideThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Anagrelide.Approved
AncrodThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ancrod.Approved, Investigational
AndrographolideThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Andrographolide.Investigational
AniracetamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aniracetam.Experimental
AnistreplaseThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Anistreplase.Approved
Antithrombin AlfaThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Antithrombin Alfa.Approved, Investigational
Antithrombin III humanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Antithrombin III human.Approved
APD791The risk or severity of adverse effects can be increased when Tranylcypromine is combined with APD791.Investigational
ApixabanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Apixaban.Approved
ApomorphineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Apomorphine.Approved, Investigational
ApraclonidineTranylcypromine may increase the alpha-adrenergic activities of Apraclonidine.Approved
ApramycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Apramycin.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Apronalide.Experimental
AptazapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aptazapine.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Arbekacin.Approved, Investigational
ArbutamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Arbutamine.Approved
ArdeparinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ardeparin.Approved, Investigational, Withdrawn
ArformoterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Arformoterol.Approved, Investigational
ArgatrobanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Aripiprazole lauroxil.Approved, Investigational
ArotinololTranylcypromine may increase the orthostatic hypotensive activities of Arotinolol.Investigational
Arsenic trioxideTranylcypromine may increase the orthostatic hypotensive activities of Arsenic trioxide.Approved, Investigational
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Tranylcypromine resulting in a loss in efficacy.Approved, Investigational
AsenapineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Asenapine.Approved
AstaxanthinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Astaxanthin.Investigational
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Tranylcypromine.Approved, Investigational, Withdrawn
AtenololTranylcypromine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Atracurium besylate.Approved
AtropineThe risk or severity of hypertension can be increased when Tranylcypromine is combined with Atropine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Azaperone.Investigational, Vet Approved
AZD-3043The risk or severity of adverse effects can be increased when Tranylcypromine is combined with AZD-3043.Investigational
AzelastineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilTranylcypromine may increase the orthostatic hypotensive activities of Azilsartan medoxomil.Approved, Investigational
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Tranylcypromine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Tranylcypromine.Approved
BalaglitazoneTranylcypromine may increase the hypoglycemic activities of Balaglitazone.Investigational
BambuterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Tranylcypromine.Experimental
BarbitalBarbital may increase the hypotensive activities of Tranylcypromine.Illicit
BarnidipineTranylcypromine may increase the orthostatic hypotensive activities of Barnidipine.Approved
BeclamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Beclamide.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bekanamycin.Experimental
BemiparinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Bemiparin.Approved, Investigational
Bempedoic acidTranylcypromine may increase the hypoglycemic activities of Bempedoic acid.Investigational
BenactyzineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Benactyzine.Withdrawn
BenazeprilTranylcypromine may increase the hypotensive activities of Benazepril.Approved, Investigational
BenazeprilatTranylcypromine may increase the hypotensive activities of Benazeprilat.Experimental
BendroflumethiazideTranylcypromine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenfluorexTranylcypromine may increase the hypoglycemic activities of Benfluorex.Investigational, Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Benperidol.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Benzoctamine.Approved
BenzphetamineTranylcypromine may increase the hypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Benzyl alcohol.Approved
BepridilTranylcypromine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeraprostThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Beraprost.Investigational
BetahistineThe metabolism of Betahistine can be decreased when combined with Tranylcypromine.Approved, Investigational
BetaxololTranylcypromine may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineTranylcypromine may increase the hypotensive activities of Bethanidine.Approved
BetrixabanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Betrixaban.Approved, Investigational
BevantololTranylcypromine may increase the hypotensive activities of Bevantolol.Approved
BezafibrateTranylcypromine may increase the hepatotoxic activities of Bezafibrate.Approved, Investigational
BezitramideThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BietaserpineTranylcypromine may increase the hypotensive activities of Bietaserpine.Experimental
BifemelaneThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bifeprunox.Investigational
BimatoprostTranylcypromine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololTranylcypromine may increase the hypotensive activities of Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bitolterol.Withdrawn
BivalirudinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Bivalirudin.Approved, Investigational
BL-1020The risk or severity of adverse effects can be increased when Tranylcypromine is combined with BL-1020.Investigational
BlonanserinThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Blonanserin.Approved, Investigational
BortezomibTranylcypromine may increase the orthostatic hypotensive activities of Bortezomib.Approved, Investigational
BosentanTranylcypromine may increase the hypotensive activities of Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Tranylcypromine.Approved
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Botulinum Toxin Type B.Approved, Investigational
BQ-123Tranylcypromine may increase the hypotensive activities of BQ-123.Investigational
BretyliumTranylcypromine may increase the hypotensive activities of Bretylium.Approved
BrinaseThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Brinase.Experimental
BrivaracetamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tranylcypromine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bromisoval.Experimental
BromocriptineTranylcypromine may increase the hypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tranylcypromine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brotizolam.Approved, Investigational, Withdrawn
BuflomedilThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Buflomedil.Experimental
BuforminTranylcypromine may increase the hypoglycemic activities of Buformin.Investigational, Withdrawn
BufotenineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bufotenine.Experimental, Illicit
BumetanideTranylcypromine may increase the orthostatic hypotensive activities of Bumetanide.Approved
BupivacaineTranylcypromine may increase the orthostatic hypotensive activities of Bupivacaine.Approved, Investigational
BupranololTranylcypromine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuprenorphineThe risk or severity of serotonin syndrome and opioid toxicity can be increased when Buprenorphine is combined with Tranylcypromine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bupropion.Approved
BupropionThe risk or severity of serotonin syndrome can be increased when Bupropion is combined with Tranylcypromine.Approved
BuspironeThe risk or severity of hypertension can be increased when Tranylcypromine is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tranylcypromine.Approved, Illicit
ButalbitalButalbital may increase the hypotensive activities of Tranylcypromine.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tranylcypromine.Approved, Illicit, Vet Approved
ButriptylineTranylcypromine may increase the serotonergic activities of Butriptyline.Approved
ButylphthalideThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Butylphthalide.Investigational
CabergolineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Cabergoline.Approved
CadralazineTranylcypromine may increase the hypotensive activities of Cadralazine.Experimental
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Tranylcypromine.Approved, Nutraceutical
CamazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Camazepam.Approved, Illicit
CanagliflozinTranylcypromine may increase the orthostatic hypotensive activities of Canagliflozin.Approved
CandesartanTranylcypromine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilTranylcypromine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilTranylcypromine may increase the hypotensive activities of Candoxatril.Experimental
CangrelorThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Cangrelor.Approved
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Tranylcypromine.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Captodiame.Approved, Investigational
CaptoprilTranylcypromine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tranylcypromine.Approved, Investigational
CarbamazepineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Carbamazepine.Approved, Investigational
CarbetocinTranylcypromine may increase the orthostatic hypotensive activities of Carbetocin.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tranylcypromine.Approved
CarbromalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carbromal.Experimental
CarbutamideTranylcypromine may increase the hypoglycemic activities of Carbutamide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tranylcypromine.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Tranylcypromine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tranylcypromine.Approved
CarmegliptinTranylcypromine may increase the hypoglycemic activities of Carmegliptin.Investigational
CaroxazoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Caroxazone.Withdrawn
CarteololTranylcypromine may increase the hypotensive activities of Carteolol.Approved
CarvedilolTranylcypromine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CathinoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cathinone.Illicit
CeliprololTranylcypromine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CerlapirdineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cerlapirdine.Investigational
CertoparinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Certoparin.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tranylcypromine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Tranylcypromine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tranylcypromine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideTranylcypromine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Tranylcypromine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorphenesin.Approved, Experimental
ChlorphentermineTranylcypromine may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideTranylcypromine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorthalidoneTranylcypromine may increase the hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tranylcypromine.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Tranylcypromine.Approved, Nutraceutical
CicletanineTranylcypromine may increase the hypotensive activities of Cicletanine.Investigational
CiglitazoneTranylcypromine may increase the hypoglycemic activities of Ciglitazone.Experimental
CilansetronThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cilansetron.Investigational
CilazaprilTranylcypromine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineTranylcypromine may increase the orthostatic hypotensive activities of Cilnidipine.Approved, Investigational
CilostazolThe metabolism of Cilostazol can be decreased when combined with Tranylcypromine.Approved, Investigational
CinitaprideThe metabolism of Cinitapride can be decreased when combined with Tranylcypromine.Approved, Investigational
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Tranylcypromine.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cinolazepam.Approved
CirazolineTranylcypromine may increase the hypertensive activities of Cirazoline.Experimental
CisaprideThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cisatracurium.Approved
CitalopramTranylcypromine may increase the serotonergic activities of Citalopram.Approved
ClemastineTranylcypromine may increase the anticholinergic activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineTranylcypromine may increase the orthostatic hypotensive activities of Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Tranylcypromine.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Tranylcypromine.Approved, Illicit
ClofarabineTranylcypromine may increase the orthostatic hypotensive activities of Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with clomethiazole.Investigational
ClomipramineTranylcypromine may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Tranylcypromine.Approved, Illicit
ClonidineTranylcypromine may increase the hypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clopenthixol.Experimental
ClopidogrelThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Clopidogrel.Approved
CloranololTranylcypromine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tranylcypromine.Approved, Illicit
CloricromenThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Cloricromen.Experimental
ClorindioneThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clotiazepam.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cloxazolam.Approved, Investigational
ClozapineTranylcypromine may increase the orthostatic hypotensive activities of Clozapine.Approved
CocaineThe risk or severity of serotonin syndrome can be increased when Cocaine is combined with Tranylcypromine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tranylcypromine.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Colistin.Approved
ConivaptanTranylcypromine may increase the orthostatic hypotensive activities of Conivaptan.Approved, Investigational
CryptenamineTranylcypromine may increase the hypotensive activities of Cryptenamine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Tranylcypromine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyclobarbital.Experimental
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Tranylcypromine.Approved
CyclopenthiazideTranylcypromine may increase the hypotensive activities of Cyclopenthiazide.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideTranylcypromine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineTranylcypromine may increase the anticholinergic activities of Cyproheptadine.Approved
Dabigatran etexilateThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Dabigatran etexilate.Approved
DalteparinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Dalteparin.Approved
DanaparoidThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Danaparoid.Approved, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tranylcypromine.Approved, Investigational
DapagliflozinTranylcypromine may increase the orthostatic hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dapiprazole.Approved
DapoxetineTranylcypromine may increase the serotonergic activities of Dapoxetine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Tranylcypromine.Approved, Investigational
DarexabanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Darexaban.Investigational
DeanolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Deanol.Experimental
DebrisoquinTranylcypromine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Decamethonium.Approved
DefibrotideThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Defibrotide.Approved, Investigational
DelaprilTranylcypromine may increase the hypotensive activities of Delapril.Investigational
DelorazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Deramciclane.Investigational
DeserpidineTranylcypromine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneTranylcypromine may increase the orthostatic hypotensive activities of Desflurane.Approved
DesipramineTranylcypromine may increase the serotonergic activities of Desipramine.Approved, Investigational
DesirudinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Desirudin.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tranylcypromine.Approved, Investigational
DesmoteplaseThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Desmoteplase.Investigational
DesvenlafaxineTranylcypromine may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tranylcypromine.Approved
DexfenfluramineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Dexfenfluramine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineTranylcypromine may increase the orthostatic hypotensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateTranylcypromine may increase the hypertensive activities of Dexmethylphenidate.Approved, Investigational
DexniguldipineTranylcypromine may increase the hypotensive activities of Dexniguldipine.Experimental
DextofisopamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dextofisopam.Investigational
DextranThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Dextran.Approved, Investigational, Vet Approved
DextroamphetamineTranylcypromine may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tranylcypromine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tranylcypromine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tranylcypromine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tranylcypromine.Approved, Illicit, Investigational, Vet Approved
DiazoxideTranylcypromine may increase the hypotensive activities of Diazoxide.Approved
DibekacinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dibekacin.Experimental
DibenzepinTranylcypromine may increase the serotonergic activities of Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dichloralphenazone.Approved, Illicit
DiclofenamideTranylcypromine may increase the orthostatic hypotensive activities of Diclofenamide.Approved, Investigational
DicoumarolThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diethyl ether.Experimental
DiethylnorspermineTranylcypromine may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Tranylcypromine.Approved, Illicit
DihydralazineTranylcypromine may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tranylcypromine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Tranylcypromine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tranylcypromine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tranylcypromine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemTranylcypromine may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tranylcypromine.Approved
DimetacrineTranylcypromine may increase the serotonergic activities of Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Dimethyltryptamine.Experimental, Illicit
DinutuximabTranylcypromine may increase the orthostatic hypotensive activities of Dinutuximab.Approved, Investigational
DiphenadioneThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Diphenadione.Experimental
DiphenhydramineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Diphenoxylate.Approved, Illicit
DipivefrinTranylcypromine may increase the hypertensive activities of Dipivefrin.Approved
DipyridamoleTranylcypromine may increase the orthostatic hypotensive activities of Dipyridamole.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Tranylcypromine.Approved
DitazoleThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ditazole.Approved, Withdrawn
DixyrazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dixyrazine.Experimental
DobutamineTranylcypromine may increase the hypertensive activities of Dobutamine.Approved
DofetilideThe metabolism of Dofetilide can be decreased when combined with Tranylcypromine.Approved, Investigational
DolasetronThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Domoic Acid.Experimental
DomperidoneThe risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Tranylcypromine is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Doramectin.Vet Approved
DorzolamideTranylcypromine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinTranylcypromine may increase the serotonergic activities of Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Doxacurium.Approved
DoxapramTranylcypromine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinTranylcypromine may increase the hypotensive activities of Doxazosin.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Doxefazepam.Experimental
DoxepinTranylcypromine may increase the serotonergic activities of Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Doxofylline.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tranylcypromine.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tranylcypromine.Experimental, Illicit
Drotrecogin alfaThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxidopaTranylcypromine may increase the hypertensive activities of Droxidopa.Approved, Investigational
DulaglutideTranylcypromine may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineThe risk or severity of orthostatic hypotension and syncope can be increased when Tranylcypromine is combined with Duloxetine.Approved
DutogliptinTranylcypromine may increase the hypoglycemic activities of Dutogliptin.Investigational
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tranylcypromine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tranylcypromine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ecopipam.Investigational
Edetate calcium disodium anhydrousThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Edetate calcium disodium anhydrous.Approved
Edetate disodium anhydrousThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Edetate disodium anhydrous.Approved, Vet Approved
Edetic AcidThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Edetic Acid.Approved, Vet Approved
EdivoxetineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Edivoxetine.Investigational
EdoxabanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Edoxaban.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tranylcypromine.Approved, Investigational
EfonidipineTranylcypromine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Eltoprazine.Investigational
EluxadolineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Emepronium.Experimental
EmpagliflozinTranylcypromine may increase the orthostatic hypotensive activities of Empagliflozin.Approved
EmylcamateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Emylcamate.Experimental
EnalaprilTranylcypromine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatTranylcypromine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineTranylcypromine may increase the hypotensive activities of Endralazine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tranylcypromine.Approved, Investigational, Vet Approved
EnglitazoneTranylcypromine may increase the hypoglycemic activities of Englitazone.Experimental
EnoxaparinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Enoxaparin.Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Tranylcypromine.Approved, Investigational
EpanololTranylcypromine may increase the hypotensive activities of Epanolol.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Eperisone.Approved, Investigational
EphedraThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinastineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Epinastine.Approved, Investigational
EplerenoneTranylcypromine may increase the orthostatic hypotensive activities of Eplerenone.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Eplivanserin.Investigational
EpoprostenolTranylcypromine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanTranylcypromine may increase the hypotensive activities of Eprosartan.Approved
EptifibatideThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Eptifibatide.Approved, Investigational
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Tranylcypromine.Approved, Nutraceutical
Ergoloid mesylateThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Ergoloid mesylate.Approved
ErgonovineTranylcypromine may increase the hypertensive activities of Ergonovine.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Tranylcypromine.Approved
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Tranylcypromine.Approved, Investigational, Vet Approved
EsatenololTranylcypromine may increase the hypotensive activities of Esatenolol.Experimental
EscitalopramTranylcypromine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EslicarbazepineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Eslicarbazepine.Approved
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Esmirtazapine.Investigational
EsmololTranylcypromine may increase the hypotensive activities of Esmolol.Approved
EsreboxetineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tranylcypromine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tranylcypromine.Approved, Investigational
Etacrynic acidTranylcypromine may increase the orthostatic hypotensive activities of Etacrynic acid.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etafedrine.Approved
EthadioneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethadione.Experimental
EthanolTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tranylcypromine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tranylcypromine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tranylcypromine.Approved
Ethyl biscoumacetateThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tranylcypromine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tranylcypromine.Approved
EtoperidoneThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tranylcypromine.Illicit, Vet Approved
EvogliptinTranylcypromine may increase the hypoglycemic activities of Evogliptin.Investigational
ExenatideTranylcypromine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Tranylcypromine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Tranylcypromine.Approved
FelodipineTranylcypromine may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoldopamTranylcypromine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fenoterol.Approved, Investigational
FentanylThe metabolism of Fentanyl can be decreased when combined with Tranylcypromine.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fenyramidol.Experimental
Ferulic acidTranylcypromine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tranylcypromine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Tranylcypromine.Approved, Investigational
FibrinolysinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Fibrinolysin.Investigational
FimasartanTranylcypromine may increase the orthostatic hypotensive activities of Fimasartan.Approved, Investigational
FlibanserinThe metabolism of Flibanserin can be decreased when combined with Tranylcypromine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fludiazepam.Approved, Illicit
FluindioneThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Fluindione.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tranylcypromine.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Tranylcypromine.Approved, Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flunitrazepam.Approved, Illicit
FluoxetineTranylcypromine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tranylcypromine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Tranylcypromine.Approved
FluvoxamineTranylcypromine may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FondaparinuxThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Fondaparinux.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Formoterol.Approved, Investigational
FosinoprilTranylcypromine may increase the hypotensive activities of Fosinopril.Approved
FosinoprilatTranylcypromine may increase the hypotensive activities of Fosinoprilat.Experimental
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Tranylcypromine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Framycetin.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Tranylcypromine.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideTranylcypromine may increase the orthostatic hypotensive activities of Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tranylcypromine.Approved, Investigational
Gabapentin enacarbilThe risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Tranylcypromine.Approved, Investigational
GabexateThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Gabexate.Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gaboxadol.Investigational
GallamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gallamine Triethiodide.Approved
Gamma hydroxybutyric acidThe risk or severity of adverse effects can be increased when Gamma hydroxybutyric acid is combined with Tranylcypromine.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gedocarnil.Experimental
GemigliptinTranylcypromine may increase the hypoglycemic activities of Gemigliptin.Investigational
GeneticinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with GENTAMICIN C1A.Experimental
GepefrineTranylcypromine may increase the hypertensive activities of Gepefrine.Experimental
GepironeThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Gepirone.Investigational
GlibornurideTranylcypromine may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideTranylcypromine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideTranylcypromine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideTranylcypromine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneTranylcypromine may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideTranylcypromine may increase the hypoglycemic activities of Glisoxepide.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Glutethimide.Approved, Illicit
GlyburideTranylcypromine may increase the hypoglycemic activities of Glyburide.Approved
GlycodiazineTranylcypromine may increase the hypoglycemic activities of Glycodiazine.Approved, Investigational
GosogliptinTranylcypromine may increase the hypoglycemic activities of Gosogliptin.Investigational
GranisetronThe risk or severity of serotonin syndrome can be increased when Granisetron is combined with Tranylcypromine.Approved, Investigational
GuanabenzTranylcypromine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelTranylcypromine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineTranylcypromine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineTranylcypromine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineTranylcypromine may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorTranylcypromine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTranylcypromine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTranylcypromine may increase the hypotensive activities of Guanoxan.Experimental
Guar gumTranylcypromine may increase the hypoglycemic activities of Guar gum.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Haloperidol.Approved
HalothaneTranylcypromine may increase the orthostatic hypotensive activities of Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Harmaline.Experimental
HeparinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Heparin.Approved, Investigational
HeptabarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tranylcypromine.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hexafluronium.Approved
HexamethoniumTranylcypromine may increase the hypotensive activities of Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hexapropymate.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Tranylcypromine.Approved
HexoprenalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hexoprenaline.Approved, Withdrawn
HydracarbazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydracarbazine.Experimental
HydralazineTranylcypromine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideTranylcypromine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneTranylcypromine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Tranylcypromine.Approved, Illicit, Investigational
HydroflumethiazideTranylcypromine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneTranylcypromine may increase the serotonergic activities of Hydromorphone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tranylcypromine.Approved, Illicit
HydroxyamphetamineTranylcypromine may increase the hypertensive activities of Hydroxyamphetamine.Approved
HydroxytyrosolThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Hydroxytyrosol.Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hypericin.Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Tranylcypromine.Approved
IbudilastThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ibudilast.Approved, Investigational
Icosapent ethylThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Icosapent ethyl.Approved, Investigational, Nutraceutical
IdalopirdineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Idalopirdine.Investigational
IdraparinuxThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Iferanserin.Investigational
IfetrobanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ifetroban.Investigational
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Tranylcypromine.Approved
IloprostTranylcypromine may increase the orthostatic hypotensive activities of Iloprost.Approved, Investigational
ImagabalinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Imagabalin.Investigational
ImidaprilTranylcypromine may increase the hypotensive activities of Imidapril.Investigational
ImipramineTranylcypromine may increase the serotonergic activities of Imipramine.Approved
Imipramine oxideTranylcypromine may increase the serotonergic activities of Imipramine oxide.Experimental
IndacaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indacaterol.Approved
IndalpineTranylcypromine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideTranylcypromine may increase the hypotensive activities of Indapamide.Approved
IndenololTranylcypromine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Indinavir can be decreased when combined with Tranylcypromine.Approved
IndiplonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indiplon.Investigational
IndobufenThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Indobufen.Investigational
IndoraminTranylcypromine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartTranylcypromine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin BeefTranylcypromine may increase the hypoglycemic activities of Insulin Beef.Approved
Insulin DegludecTranylcypromine may increase the hypoglycemic activities of Insulin Degludec.Approved
Insulin DetemirTranylcypromine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineTranylcypromine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineTranylcypromine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanTranylcypromine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproTranylcypromine may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin peglisproTranylcypromine may increase the hypoglycemic activities of Insulin peglispro.Investigational
Insulin PorkTranylcypromine may increase the hypoglycemic activities of Insulin Pork.Approved
Iofetamine I-123Tranylcypromine may increase the hypertensive activities of Iofetamine I-123.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Iprazochrome.Experimental
IprindoleTranylcypromine may increase the serotonergic activities of Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Iproniazid.Withdrawn
IrbesartanTranylcypromine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isepamicin.Experimental
IsocarboxazidThe therapeutic efficacy of Tranylcypromine can be increased when used in combination with Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoetarine.Approved
IsofluraneTranylcypromine may increase the orthostatic hypotensive activities of Isoflurane.Approved, Vet Approved
IsomethepteneTranylcypromine may increase the sympathomimetic activities of Isometheptene.Approved
IsoniazidThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Isoniazid.Approved, Investigational
IsoprenalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoprenaline.Approved, Investigational
Isosorbide dinitrateTranylcypromine may increase the orthostatic hypotensive activities of Isosorbide dinitrate.Approved, Investigational
Isosorbide MononitrateTranylcypromine may increase the orthostatic hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineTranylcypromine may increase the orthostatic hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineTranylcypromine may increase the hypotensive activities of Isradipine.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tranylcypromine.Approved, Vet Approved
KetanserinThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tranylcypromine.Approved, Investigational
KRP-104Tranylcypromine may increase the hypoglycemic activities of KRP-104.Investigational
L-TryptophanThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Tranylcypromine.Approved, Nutraceutical, Withdrawn
LabetalolTranylcypromine may increase the hypotensive activities of Labetalol.Approved
LacosamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tranylcypromine.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lanicemine.Investigational
LasmiditanThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Lasmiditan.Investigational
LatanoprostTranylcypromine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LepirudinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Lepirudin.Approved
LercanidipineTranylcypromine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LetaxabanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Letaxaban.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tranylcypromine.Approved, Investigational
LevobunololTranylcypromine may increase the orthostatic hypotensive activities of Levobunolol.Approved
LevobupivacaineTranylcypromine may increase the orthostatic hypotensive activities of Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tranylcypromine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levodopa.Approved
LevodopaThe risk or severity of hypotension and orthostatic hypotension can be increased when Tranylcypromine is combined with Levodopa.Approved
Levomethadyl acetateThe risk or severity of adverse effects can be increased when Levomethadyl acetate is combined with Tranylcypromine.Approved, Investigational
LevomilnacipranTranylcypromine may increase the serotonergic activities of Levomilnacipran.Approved, Investigational
LevonordefrinTranylcypromine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tranylcypromine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levosalbutamol.Approved, Investigational
LevosimendanTranylcypromine may increase the orthostatic hypotensive activities of Levosimendan.Approved, Investigational
LinagliptinTranylcypromine may increase the hypoglycemic activities of Linagliptin.Approved
LincomycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Linezolid.Approved, Investigational
LinsidomineTranylcypromine may increase the hypotensive activities of Linsidomine.Experimental
LiothyronineThe metabolism of Liothyronine can be decreased when combined with Tranylcypromine.Approved, Vet Approved
LiraglutideTranylcypromine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineTranylcypromine may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilTranylcypromine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Tranylcypromine.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lithium carbonate.Approved
LixisenatideTranylcypromine may increase the hypoglycemic activities of Lixisenatide.Approved
LobeglitazoneTranylcypromine may increase the hypoglycemic activities of Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Tranylcypromine.Illicit
LofepramineTranylcypromine may increase the serotonergic activities of Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Tranylcypromine can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tranylcypromine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tranylcypromine.Approved
LorcaserinThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lormetazepam.Approved
LortalamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lortalamine.Experimental
LosartanTranylcypromine may increase the hypotensive activities of Losartan.Approved
LovastatinThe metabolism of Lovastatin can be decreased when combined with Tranylcypromine.Approved, Investigational
LoxapineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Loxapine.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Lurasidone.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with m-Chlorophenylpiperazine.Investigational
MacitentanTranylcypromine may increase the hypotensive activities of Macitentan.Approved
Magnesium acetateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Tranylcypromine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium Trisilicate.Approved
ManidipineTranylcypromine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolTranylcypromine may increase the orthostatic hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Maprotiline.Approved, Investigational
MazindolThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mebutamate.Approved
MecamylamineTranylcypromine may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MecaserminTranylcypromine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Tranylcypromine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Medifoxamine.Experimental
MedrysoneThe metabolism of Medrysone can be decreased when combined with Tranylcypromine.Approved
MelagatranThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenTranylcypromine may increase the serotonergic activities of Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Melperone.Approved, Investigational
MephedroneTranylcypromine may increase the hypertensive activities of Mephedrone.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mephenoxalone.Experimental
MephentermineTranylcypromine may increase the hypertensive activities of Mephentermine.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mephenytoin.Approved, Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tranylcypromine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Tranylcypromine.Experimental
MequitazineTranylcypromine may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mesoridazine.Approved, Investigational
MetahexamideTranylcypromine may increase the hypoglycemic activities of Metahexamide.Experimental
MetaraminolTranylcypromine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metergoline.Experimental
MetforminTranylcypromine may increase the hypoglycemic activities of Metformin.Approved
MethacyclineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methacycline.Approved, Investigational
Methadyl acetateThe risk or severity of adverse effects can be increased when Methadyl acetate is combined with Tranylcypromine.Approved, Illicit
MethamphetamineTranylcypromine may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metharbital.Withdrawn
MethazolamideTranylcypromine may increase the orthostatic hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tranylcypromine.Approved, Vet Approved
MethohexitalMethohexital may increase the hypotensive activities of Tranylcypromine.Approved
MethoserpidineTranylcypromine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineTranylcypromine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineTranylcypromine may increase the hypertensive activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tranylcypromine.Approved
MethyclothiazideTranylcypromine may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaTranylcypromine may decrease the hypotensive activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tranylcypromine.Experimental
Methylene blueTranylcypromine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methylpentynol.Experimental
MethylphenidateTranylcypromine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylphenidateThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Tranylcypromine.Approved
MethylthioniniumThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Methylthioninium.Experimental, Investigational
MethyprylonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methysergide.Approved
MetipranololTranylcypromine may increase the hypotensive activities of Metipranolol.Approved
MetocurineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metocurine Iodide.Approved, Withdrawn
MetolazoneTranylcypromine may increase the hypotensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Tranylcypromine.Approved, Investigational
MetyrosineTranylcypromine may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mianserin.Approved, Investigational
MibefradilTranylcypromine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MicronomicinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tranylcypromine.Approved, Illicit
MidodrineTranylcypromine may increase the hypertensive activities of Midodrine.Approved
MidomafetamineTranylcypromine may increase the hypertensive activities of Midomafetamine.Experimental, Illicit, Investigational
MifepristoneTranylcypromine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolTranylcypromine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranTranylcypromine may increase the serotonergic activities of Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Investigational
MinoxidilTranylcypromine may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideTranylcypromine may increase the hypoglycemic activities of Mitiglinide.Approved, Investigational
MivacuriumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mivacurium.Approved
MK-212The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with MK-212.Investigational
MMDATranylcypromine may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Moclobemide.Approved, Investigational
MoexiprilTranylcypromine may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineTranylcypromine may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mosapramine.Experimental
MosaprideThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Mosapride.Investigational
MoxonidineTranylcypromine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MRK-409The risk or severity of adverse effects can be increased when Tranylcypromine is combined with MRK-409.Experimental
MuzolimineTranylcypromine may increase the hypotensive activities of Muzolimine.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Investigational
NadololTranylcypromine may increase the hypotensive activities of Nadolol.Approved
NadroparinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Nadroparin.Approved, Investigational
NafamostatThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Nafamostat.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Naftidrofuryl.Experimental
NaftopidilTranylcypromine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tranylcypromine.Approved
NaltrexoneThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Naltrexone.Approved, Investigational, Vet Approved
NaluzotanThe metabolism of Naluzotan can be decreased when combined with Tranylcypromine.Investigational
NaphazolineTranylcypromine may increase the hypertensive activities of Naphazoline.Approved, Investigational
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Tranylcypromine.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Naronapride.Investigational
NateglinideTranylcypromine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NBI-6024Tranylcypromine may increase the hypoglycemic activities of NBI-6024.Investigational
NeamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Neamine.Experimental
NebivololTranylcypromine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneTranylcypromine may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nefiracetam.Investigational
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Tranylcypromine.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Neosaxitoxin.Investigational
NesiritideTranylcypromine may increase the orthostatic hypotensive activities of Nesiritide.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Netilmicin.Approved, Investigational
NetoglitazoneTranylcypromine may increase the hypoglycemic activities of Netoglitazone.Experimental
NevirapineThe metabolism of Nevirapine can be decreased when combined with Tranylcypromine.Approved
NialamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Niaprazine.Experimental
NicardipineTranylcypromine may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicomorphineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Nicomorphine.Experimental
NifedipineTranylcypromine may increase the orthostatic hypotensive activities of Nifedipine.Approved
NiguldipineTranylcypromine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineTranylcypromine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineTranylcypromine may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineTranylcypromine may increase the hypotensive activities of Nisoldipine.Approved
NisoxetineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tranylcypromine.Approved
NitrendipineTranylcypromine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideTranylcypromine may increase the orthostatic hypotensive activities of Nitric Oxide.Approved
NitroaspirinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Nitroaspirin.Investigational
NitroglycerinTranylcypromine may increase the orthostatic hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideTranylcypromine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidTranylcypromine may increase the orthostatic hypotensive activities of Nitrous acid.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tranylcypromine.Approved, Vet Approved
NN344Tranylcypromine may increase the hypoglycemic activities of NN344.Investigational
NomifensineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nordazepam.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Tranylcypromine.Approved, Illicit
NortriptylineTranylcypromine may increase the serotonergic activities of Nortriptyline.Approved
NutmegThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Nutmeg.Approved
ObinutuzumabTranylcypromine may increase the orthostatic hypotensive activities of Obinutuzumab.Approved, Investigational
OcinaplonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ocinaplon.Investigational
OctamoxinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Olanzapine.Approved, Investigational
OlmesartanTranylcypromine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tranylcypromine.Approved
OmapatrilatTranylcypromine may increase the hypotensive activities of Omapatrilat.Investigational
OmarigliptinTranylcypromine may increase the hypoglycemic activities of Omarigliptin.Investigational
OndansetronThe risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Tranylcypromine.Approved
OpicaponeThe risk or severity of adverse effects can be increased when Opicapone is combined with Tranylcypromine.Approved, Investigational
OpipramolTranylcypromine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Tranylcypromine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Orciprenaline.Approved
OrphenadrineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Osanetant.Investigational
OtamixabanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Otamixaban.Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxaprotiline.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tranylcypromine.Approved
Oxazepam acetateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxazepam acetate.Experimental
OxcarbazepineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxprenololTranylcypromine may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneTranylcypromine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineTranylcypromine may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tranylcypromine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxypertine.Experimental
OxytetracyclineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PaclitaxelTranylcypromine may increase the orthostatic hypotensive activities of Paclitaxel.Approved, Vet Approved
PagocloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pagoclone.Investigational
PaliperidoneThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Paliperidone.Approved
PalonosetronThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Palonosetron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pancuronium.Approved
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Tranylcypromine.Approved
PapaverineTranylcypromine may increase the orthostatic hypotensive activities of Papaverine.Approved, Investigational
ParaldehydeTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pargyline.Approved
ParnaparinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Parnaparin.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Paromomycin.Approved, Investigational
ParoxetineTranylcypromine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololTranylcypromine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Penimepicycline.Experimental
PentamidineTranylcypromine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tranylcypromine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Tranylcypromine.Approved, Investigational, Vet Approved
PentoliniumTranylcypromine may increase the hypotensive activities of Pentolinium.Approved
Pentosan PolysulfateThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Pentoxifylline.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
PerazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perazine.Approved, Investigational
PergolideTranylcypromine may increase the hypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilTranylcypromine may increase the hypotensive activities of Perindopril.Approved
PerindoprilatTranylcypromine may increase the hypotensive activities of Perindoprilat.Experimental
PerospironeThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perphenazine.Approved
Perphenazine enanthateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perphenazine enanthate.Experimental
PethidineThe risk or severity of serotonin syndrome and opioid toxicity can be increased when Tranylcypromine is combined with Pethidine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Tranylcypromine is combined with PF-00610355.Investigational
PhenacemideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Tranylcypromine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phencyclidine.Illicit
PhendimetrazineTranylcypromine may increase the hypertensive activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pheneturide.Experimental
PhenforminTranylcypromine may increase the hypoglycemic activities of Phenformin.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenibut.Experimental
PhenindioneThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Phenindione.Approved, Investigational
PheniprazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pheniprazine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Tranylcypromine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Tranylcypromine.Experimental
PhenoxybenzamineTranylcypromine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenprobamate.Experimental
PhenprocoumonThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Phenprocoumon.Approved, Investigational
PhensuximideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phensuximide.Approved
PhentermineTranylcypromine may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineTranylcypromine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineTranylcypromine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Tranylcypromine.Approved, Vet Approved
PholcodinePholcodine may increase the serotonergic activities of Tranylcypromine.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Tranylcypromine.Investigational
PicotamideThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Picotamide.Experimental
PimavanserinThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pimozide.Approved
PinacidilTranylcypromine may increase the hypotensive activities of Pinacidil.Approved
PinazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pinazepam.Experimental
PindololThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Pindolol.Approved, Investigational
PioglitazoneTranylcypromine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pipotiazine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Tranylcypromine.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pirlindole.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Tranylcypromine.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pivhydrazine.Withdrawn
PizotifenTranylcypromine may increase the anticholinergic activities of Pizotifen.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Plazomicin.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideTranylcypromine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tranylcypromine.Approved
Potassium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PractololTranylcypromine may increase the hypotensive activities of Practolol.Approved
PramipexoleTranylcypromine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideTranylcypromine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasugrelThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Prasugrel.Approved
PrazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prazepam.Approved, Illicit
PrazosinTranylcypromine may increase the hypotensive activities of Prazosin.Approved
PregabalinThe therapeutic efficacy of Tranylcypromine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pridinol.Experimental
PrimidonePrimidone may increase the hypotensive activities of Tranylcypromine.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Procainamide.Approved
ProcaineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Tranylcypromine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prochlorperazine.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Progabide.Approved, Investigational
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Tranylcypromine.Approved, Vet Approved
PromazineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Promethazine.Approved, Investigational
PropacetamolThe metabolism of Propacetamol can be decreased when combined with Tranylcypromine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propanidid.Experimental
PropericiazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propericiazine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propiopromazine.Vet Approved
PropofolTranylcypromine may increase the orthostatic hypotensive activities of Propofol.Approved, Investigational, Vet Approved
PropranololTranylcypromine may increase the hypotensive activities of Propranolol.Approved, Investigational
Protein CThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Protein C.Approved
Protein S humanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Protein S human.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prothipendyl.Investigational
ProtocatechualdehydeThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Protocatechualdehyde.Approved
ProtokylolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Protokylol.Approved, Vet Approved
ProtriptylineTranylcypromine may increase the serotonergic activities of Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Proxibarbal.Experimental
PRX-08066The risk or severity of adverse effects can be increased when Tranylcypromine is combined with PRX-08066.Investigational
PseudoephedrineTranylcypromine may increase the hypertensive activities of Pseudoephedrine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tranylcypromine.Approved, Illicit
QuercetinThe risk or severity of adverse effects can be increased when Quercetin is combined with Tranylcypromine.Experimental, Investigational
QuetiapineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Quetiapine.Approved
QuinaprilTranylcypromine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinaprilatTranylcypromine may increase the hypotensive activities of Quinaprilat.Experimental
QuinidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Quinine.Approved
QuinupramineTranylcypromine may increase the serotonergic activities of Quinupramine.Experimental
RacepinephrineTranylcypromine may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Raclopride.Investigational
RamatrobanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ramatroban.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ramelteon.Approved, Investigational
RamiprilTranylcypromine may increase the hypotensive activities of Ramipril.Approved
RamiprilatTranylcypromine may increase the hypotensive activities of Ramiprilat.Experimental
RamosetronThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ramosetron.Approved, Investigational
RanolazineThe metabolism of Ranolazine can be decreased when combined with Tranylcypromine.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Rapacuronium.Approved, Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Rasagiline.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Reboxetine.Approved, Investigational
RelcovaptanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Relcovaptan.Investigational
RemacemideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Remacemide.Investigational
RemifentanilThe risk or severity of hypertension, serotonin syndrome, and CNS depression can be increased when Tranylcypromine is combined with Remifentanil.Approved
RemikirenTranylcypromine may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Renzapride.Investigational
RepaglinideTranylcypromine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RepinotanThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Reposal.Approved
RescinnamineTranylcypromine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Reserpine.Approved, Investigational
ResveratrolThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Resveratrol.Approved, Experimental, Investigational
ReteplaseThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Reteplase.Approved, Investigational
ReviparinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Reviparin.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ribostamycin.Approved, Investigational
RidogrelThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ridogrel.Approved
RilmenidineTranylcypromine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Tranylcypromine.Approved
RiluzoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Riluzole.Approved, Investigational
RiociguatTranylcypromine may increase the hypotensive activities of Riociguat.Approved
RisperidoneTranylcypromine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinTranylcypromine may increase the serotonergic activities of Ritanserin.Investigational
RitobegronTranylcypromine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ritodrine.Approved, Investigational
RitonavirThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Ritonavir.Approved, Investigational
RivaroxabanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Rivaroxaban.Approved
RivoglitazoneTranylcypromine may increase the hypoglycemic activities of Rivoglitazone.Experimental, Investigational
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Tranylcypromine.Approved
RocuroniumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Romifidine.Vet Approved
RopiniroleTranylcypromine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineTranylcypromine may increase the orthostatic hypotensive activities of Ropivacaine.Approved
RosiglitazoneTranylcypromine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineTranylcypromine may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Tranylcypromine is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tranylcypromine.Approved
SacubitrilTranylcypromine may increase the orthostatic hypotensive activities of Sacubitril.Approved
SafinamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salmeterol.Approved
SaprisartanTranylcypromine may increase the hypotensive activities of Saprisartan.Experimental
SaredutantThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Saredutant.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sarpogrelate.Investigational
SaruplaseThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Saruplase.Experimental
SaxagliptinTranylcypromine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tranylcypromine.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Tranylcypromine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagTranylcypromine may increase the hypotensive activities of Selexipag.Approved
SemaglutideTranylcypromine may increase the hypoglycemic activities of Semaglutide.Approved, Investigational
SerotoninThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineTranylcypromine may increase the serotonergic activities of Sertraline.Approved
SetiptilineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Setiptiline.Approved
SevofluraneTranylcypromine may increase the orthostatic hypotensive activities of Sevoflurane.Approved, Vet Approved
SibutramineTranylcypromine may increase the serotonergic activities of Sibutramine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be decreased when combined with Tranylcypromine.Approved, Investigational
SisomicinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sisomicin.Investigational
SitagliptinTranylcypromine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanTranylcypromine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Sodium Citrate.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
SotagliflozinTranylcypromine may increase the hypoglycemic activities of Sotagliflozin.Investigational
SotalolTranylcypromine may increase the orthostatic hypotensive activities of Sotalol.Approved
SpiraprilTranylcypromine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneTranylcypromine may increase the orthostatic hypotensive activities of Spironolactone.Approved
St. John's WortThe risk or severity of serotonin syndrome can be increased when St. John's Wort is combined with Tranylcypromine.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Tranylcypromine.Approved
StreptokinaseTranylcypromine may increase the orthostatic hypotensive activities of Streptokinase.Approved, Investigational
StreptomycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Succinylcholine.Approved
SufentanilThe risk or severity of hypertension, serotonin syndrome, and CNS depression can be increased when Tranylcypromine is combined with Sufentanil.Approved, Investigational
SulfadiazineTranylcypromine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleTranylcypromine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfinpyrazoneThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Sulfinpyrazone.Approved
SulfisoxazoleTranylcypromine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulodexideThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Sulodexide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sultopride.Experimental
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Tranylcypromine.Approved, Investigational
SunitinibTranylcypromine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Talbutal.Approved, Illicit
TalinololTranylcypromine may increase the hypotensive activities of Talinolol.Investigational
TalopramThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Talopram.Experimental
TamsulosinTranylcypromine may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Tandospirone.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Tranylcypromine.Approved
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tasimelteon.Approved, Investigational
TaspoglutideTranylcypromine may increase the hypoglycemic activities of Taspoglutide.Investigational
TD-8954The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with TD-8954.Investigational
TegafurThe serum concentration of the active metabolites of Tegafur can be reduced when Tegafur is used in combination with Tranylcypromine resulting in a loss in efficacy.Approved, Investigational
TegaserodThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Tegaserod.Approved, Investigational, Withdrawn
TelmisartanTranylcypromine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tranylcypromine.Approved, Investigational
TemocaprilTranylcypromine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Tenecteplase.Approved
TeneligliptinTranylcypromine may increase the hypoglycemic activities of Teneligliptin.Investigational
TerazosinTranylcypromine may increase the hypotensive activities of Terazosin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Terbutaline.Approved
TesmilifeneThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Tesmilifene.Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetrabenazine.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe metabolism of Tetrahydrocannabivarin can be decreased when combined with Tranylcypromine.Investigational
TetrahydropalmatineTranylcypromine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetrodotoxin.Investigational
TetryzolineThe risk or severity of hypertension can be increased when Tranylcypromine is combined with Tetryzoline.Approved
ThalidomideTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Tranylcypromine.Approved
ThiamylalThiamylal may increase the hypotensive activities of Tranylcypromine.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThiopental may increase the hypotensive activities of Tranylcypromine.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Tranylcypromine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Tranylcypromine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Tranylcypromine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiapride.Approved, Investigational
TicagrelorThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ticlopidine.Approved
TicrynafenTranylcypromine may increase the hypotensive activities of Ticrynafen.Withdrawn
TigecyclineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Tranylcypromine.Experimental
TimololTranylcypromine may increase the hypotensive activities of Timolol.Approved
TinzaparinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Tinzaparin.Approved
TioclomarolThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Tioclomarol.Experimental
TirofibanThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Tirofiban.Approved
TizanidineTranylcypromine may increase the orthostatic hypotensive activities of Tizanidine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tobramycin.Approved, Investigational
TocopherylquinoneTranylcypromine may increase the hypotensive activities of Tocopherylquinone.Experimental, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tofisopam.Approved
TolazamideTranylcypromine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineTranylcypromine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideTranylcypromine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeTranylcypromine may increase the orthostatic hypotensive activities of Tolcapone.Approved, Withdrawn
TolonidineTranylcypromine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tolperisone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Tranylcypromine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tranylcypromine.Approved
TorasemideTranylcypromine may increase the hypotensive activities of Torasemide.Approved
TramadolThe risk or severity of serotonin syndrome and seizure can be increased when Tranylcypromine is combined with Tramadol.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tramiprosate.Investigational
TrandolaprilTranylcypromine may increase the hypotensive activities of Trandolapril.Approved
TranilastThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Tranilast.Approved, Investigational
TrapidilThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Trapidil.Approved
TravoprostTranylcypromine may increase the hypotensive activities of Travoprost.Approved
TrazodoneTranylcypromine may increase the serotonergic activities of Trazodone.Approved, Investigational
TreprostinilTranylcypromine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinTranylcypromine may increase the orthostatic hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneTranylcypromine may increase the orthostatic hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tranylcypromine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideTranylcypromine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triclofos.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triflupromazine.Approved, Vet Approved
TriflusalThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Triflusal.Approved, Investigational
TrimazosinTranylcypromine may increase the hypotensive activities of Trimazosin.Experimental
TrimethadioneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trimethadione.Approved
TrimethaphanTranylcypromine may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineTranylcypromine may increase the serotonergic activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tranylcypromine.Approved
TroglitazoneTranylcypromine may increase the hypoglycemic activities of Troglitazone.Investigational, Withdrawn
TropisetronThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tropisetron.Approved, Investigational
TroxerutinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Troxerutin.Investigational
TubocurarineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tubocurarine.Approved
UnoprostoneTranylcypromine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilTranylcypromine may increase the hypotensive activities of Urapidil.Investigational
UrokinaseThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Urokinase.Approved, Investigational, Withdrawn
VabicaserinThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Vabicaserin.Investigational
ValerianThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Valerian.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Valnoctamide.Investigational
Valproate bismuthThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Valproate bismuth.Approved
Valproic AcidThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Valpromide.Experimental
ValsartanTranylcypromine may increase the hypotensive activities of Valsartan.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vecuronium.Approved
VenlafaxineTranylcypromine may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Veralipride.Experimental
VerapamilTranylcypromine may increase the orthostatic hypotensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Tranylcypromine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Tranylcypromine.Approved
VildagliptinTranylcypromine may increase the hypoglycemic activities of Vildagliptin.Approved, Investigational
ViloxazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vinbarbital.Experimental
VincamineTranylcypromine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vinylbital.Experimental
VogliboseTranylcypromine may increase the hypoglycemic activities of Voglibose.Approved, Investigational
VorapaxarThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Vorapaxar.Approved
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Tranylcypromine.Approved, Investigational
WarfarinThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Warfarin.Approved
WortmanninThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Wortmannin.Experimental
XimelagatranThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ximelagatran.Approved, Investigational, Withdrawn
XipamideTranylcypromine may increase the hypotensive activities of Xipamide.Experimental
XP19986The risk or severity of adverse effects can be increased when Tranylcypromine is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Xylazine.Vet Approved
XylometazolineTranylcypromine may increase the hypertensive activities of Xylometazoline.Approved, Investigational
YKP-1358The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with YKP-1358.Investigational
YohimbineThe therapeutic efficacy of Tranylcypromine can be increased when used in combination with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tranylcypromine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tranylcypromine.Approved
ZimelidineTranylcypromine may increase the serotonergic activities of Zimelidine.Withdrawn
Zinc citrateThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Zinc citrate.Approved
ZiprasidoneThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Ziprasidone.Approved
ZofenoprilTranylcypromine may increase the hypotensive activities of Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zolazepam.Vet Approved
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Tranylcypromine.Approved, Investigational
ZolpidemTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tranylcypromine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tranylcypromine.Approved
ZotepineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid aged foods (chesse, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid St. John's Wort.

References

General References
  1. Frieling H, Bleich S: Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73. [PubMed:16927039]
  2. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774]
External Links
KEGG Drug
D08625
KEGG Compound
C07155
PubChem Compound
5530
PubChem Substance
46505832
ChemSpider
5329
BindingDB
50113851
ChEBI
131512
ChEMBL
CHEMBL313833
Therapeutic Targets Database
DAP000081
PharmGKB
PA451741
HET
GJZ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Tranylcypromine
ATC Codes
N06AF04 — Tranylcypromine
AHFS Codes
  • 28:16.04.12 — Monoamine Oxidase Inhibitors
FDA label
Download (152 KB)
MSDS
Download (38.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedNot AvailableTo Determine the Bioavailability of Tranylcypromine1
1RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Leukemias / Myelodysplastic Syndromes1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
3Not Yet RecruitingTreatmentIntracerebral Hemorrhage / Stroke Hemorrhagic1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentAcute Upper Gastrointestinal Hemorrhage1
4CompletedPreventionKnee Osteoarthritis (Knee OA)1
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentBipolar Disorder I or II1
4CompletedTreatmentDepression1
4CompletedTreatmentHaemorrhage1
4Not Yet RecruitingPreventionKnee Osteoarthritis (Knee OA)3
4RecruitingTreatmentHip Replacement, Total1
4TerminatedTreatmentMajor Depressive Disorder (MDD)2
Not AvailableCompletedTreatmentBipolar Disorder (BD)1
Not AvailableCompletedTreatmentBlood Loss / Congenital Heart Disease (CHD)1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Par pharmaceutical inc
Packagers
  • GlaxoSmithKline Inc.
  • Kaiser Foundation Hospital
  • Kali Laboratories Inc.
  • Par Pharmaceuticals
  • Physicians Total Care Inc.
Dosage forms
FormRouteStrength
TabletOral10 mg
Tablet, film coatedOral10 mg/1
TabletOral10 mg/1
Prices
Unit descriptionCostUnit
Parnate 10 mg tablet1.64USD tablet
Tranylcypromine Sulfate 10 mg tablet1.3USD tablet
Tranylcypromine sulf 10 mg tablet1.25USD tablet
Parnate 10 mg Tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)79-80 °C at 1.50E+00 mm HgNot Available
water solubility4.86E+004 mg/LNot Available
logP1.58HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility1.49 mg/mLALOGPS
logP1.5ALOGPS
logP1.34ChemAxon
logS-2ALOGPS
pKa (Strongest Basic)9.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity41.7 m3·mol-1ChemAxon
Polarizability15.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9383
Caco-2 permeable+0.7935
P-glycoprotein substrateNon-substrate0.8349
P-glycoprotein inhibitor INon-inhibitor0.9566
P-glycoprotein inhibitor IINon-inhibitor0.9899
Renal organic cation transporterNon-inhibitor0.8659
CYP450 2C9 substrateNon-substrate0.8439
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7604
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.8659
CYP450 2D6 inhibitorNon-inhibitor0.7879
CYP450 2C19 inhibitorInhibitor0.8748
CYP450 3A4 inhibitorNon-inhibitor0.9372
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6942
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6686
BiodegradationReady biodegradable0.5525
Rat acute toxicity2.4266 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9807
hERG inhibition (predictor II)Non-inhibitor0.9378
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Benzene and substituted derivatives / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
Aralkylamine / Benzenoid / Monocyclic benzene moiety / Organopnictogen compound / Hydrocarbon derivative / Primary amine / Primary aliphatic amine / Aromatic homomonocyclic compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163]
  3. Shioda K, Nisijima K, Yoshino T, Kato S: Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett. 2010 Oct 4;482(3):216-9. doi: 10.1016/j.neulet.2010.07.039. Epub 2010 Jul 23. [PubMed:20655983]
  4. Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol. 2006 Mar;17(2):151-9. [PubMed:16495723]
  5. Lang W, Masucci JA, Caldwell GW, Hageman W, Hall J, Jones WJ, Rafferty BM: Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Anal Biochem. 2004 Oct 1;333(1):79-87. [PubMed:15351283]
  6. Shioda K, Nisijima K, Yoshino T, Kato S: Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):633-40. [PubMed:15276688]
  7. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511]
  8. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774]
  9. Cohen C, Curet O, Perrault G, Sanger DJ: Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav. 1999 Nov;64(3):535-9. [PubMed:10548268]
  10. Wiest SA, Steinberg MI: 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):209-16. [PubMed:10494892]
  11. Loscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92. [PubMed:10027835]
  12. Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. [PubMed:8749840]
  13. Finberg JP, Youdim MB: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002 Dec;43(7):1110-8. [PubMed:12504917]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163]
  3. Shioda K, Nisijima K, Yoshino T, Kato S: Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett. 2010 Oct 4;482(3):216-9. doi: 10.1016/j.neulet.2010.07.039. Epub 2010 Jul 23. [PubMed:20655983]
  4. Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol. 2006 Mar;17(2):151-9. [PubMed:16495723]
  5. Lang W, Masucci JA, Caldwell GW, Hageman W, Hall J, Jones WJ, Rafferty BM: Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Anal Biochem. 2004 Oct 1;333(1):79-87. [PubMed:15351283]
  6. Shioda K, Nisijima K, Yoshino T, Kato S: Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):633-40. [PubMed:15276688]
  7. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511]
  8. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774]
  9. Cohen C, Curet O, Perrault G, Sanger DJ: Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav. 1999 Nov;64(3):535-9. [PubMed:10548268]
  10. Wiest SA, Steinberg MI: 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):209-16. [PubMed:10494892]
  11. Loscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92. [PubMed:10027835]
  12. Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. [PubMed:8749840]
  13. Finberg JP, Youdim MB: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002 Dec;43(7):1110-8. [PubMed:12504917]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Taavitsainen P, Juvonen R, Pelkonen O: In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos. 2001 Mar;29(3):217-22. [PubMed:11181487]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
4. Cytochrome P450 2C19
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Stadel R, Yang J, Nalwalk JW, Phillips JG, Hough LB: High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain. Drug Metab Dispos. 2008 Mar;36(3):614-21. Epub 2007 Dec 19. [PubMed:18094038]
  2. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on September 17, 2018 20:45